Generic selectors
Exact matches only
Search in title
Search in content
Post Type Selectors
post
Last Updated: April 2, 2026, 3:30 am
Author: Getaka|Social: XLinkedIn

Pharmaids Pharmaceuticals Ltd: Intrinsic Value & Share Price Analysis

Fair Value

₹29.33Fairly Valued by 2.55%vs CMP ₹28.60

P/E (15.0) × ROE (16.3%) × BV (₹14.70) × DY (2.00%)

Defaults: P/E=15

₹14.20Overvalued by 50.35%vs CMP ₹28.60
MoS: -101.4% (Negative)Confidence: 55/100 (Moderate)Models: All 4: Overvalued
ModelCategoryValueWeightSignal
PE-ROEEarnings₹21.2041%Over (-25.9%)
Net Asset ValueAssets₹14.7224%Over (-48.5%)
ROCE CapitalReturns₹2.7916%Over (-90.2%)
Revenue MultipleRevenue₹8.0718%Over (-71.8%)
Consensus (4 models)₹14.20100%Overvalued
Key Drivers: EPS CAGR -27.7% drags value — could be higher if earnings stabilize. | Wide model spread (₹3–₹21) — high uncertainty.

PE-ROE · Graham · EPV · DCF · NAV · EV/EBITDA · DDM · Earnings Yield · ROCE Capital · Revenue Multiple | CoE: 12% · Terminal: 4% · EPS CAGR: -27.7% · Defaults: P/E=15

*Investments are subject to market risks

Investment Snapshot

57
Pharmaids Pharmaceuticals Ltd scores 57/100 (Average)
Based on 5 dimensions: health, institutional flow, earnings quality, momentum, and peer comparison
Stock Health49/100 · Moderate
ROCE 17.4% GoodROE 16.3% GoodD/E 0.00 Low debtInterest Coverage 0.0x RiskyProfitable 0/5 years Inconsistent
Smart Money50/100 · Moderate
Promoter holding at 33.0% Stable
Earnings Quality50/100 · Moderate
OPM contracting (2% → -74%) DecliningWorking capital: -160 days (improving) Efficient
Quarterly Momentum80/100 · Strong
Revenue (4Q): +24% YoY AcceleratingOPM: -46.2% (up 15.1% YoY) Margin expansion
Industry Rank60/100 · Moderate
ROCE 17.4% vs industry 16.4% Average3Y sales CAGR: 68% High growth

Weights: Health 30% · Earnings Quality 25% · Momentum 20% · Industry Rank 15% · Smart Money 10%. Scores are computed from reported financials and recalculated daily. Not investment advice.

Share Price and Basic Stock Data

Last Updated: April 2, 2026, 3:30 am

Market Cap 101 Cr.
Current Price 28.6
Intrinsic Value₹14.20
High / Low 73.4/27.1
Stock P/E
Book Value 14.7
Dividend Yield0.00 %
ROCE17.4 %
ROE16.3 %
Face Value 10.0
PEG Ratio0.00

Stock P/E, Current Price, and Intrinsic Value Over Time

View Share Price Target for Pharmaids Pharmaceuticals Ltd

Competitors

Stock Name ⇩Market Cap ⇩Current Price ⇩High / Low ⇩Stock P/E ⇩Book Value ⇩Dividend Yield ⇩ROCE ⇩ROE ⇩Face Value ⇩
Pharmaids Pharmaceuticals Ltd 101 Cr. 28.6 73.4/27.1 14.70.00 %17.4 %16.3 % 10.0
Par Drugs & Chemicals Ltd 102 Cr. 82.6 122/78.07.31 86.50.00 %18.4 %13.6 % 10.0
Bal Pharma Ltd 103 Cr. 64.9 129/59.712.7 49.21.85 %10.1 %9.66 % 10.0
Lactose (India) Ltd 106 Cr. 84.2 137/76.021.9 49.60.00 %12.9 %9.69 % 10.0
Alpa Laboratories Ltd 106 Cr. 50.2 120/46.08.95 92.00.00 %15.0 %11.5 % 10.0
Industry Average19,815.15 Cr1,053.8453.84201.200.39%16.35%15.16%6.10

All Competitor Stocks of Pharmaids Pharmaceuticals Ltd

Quarterly Result

MetricDec 2022Mar 2023Jun 2023Sep 2023Dec 2023Mar 2024Jun 2024Sep 2024Dec 2024Mar 2025Jun 2025Sep 2025Dec 2025
Sales 0.000.000.000.000.025.814.735.244.714.776.668.615.43
Expenses 0.698.601.611.022.4511.398.147.657.608.6712.0313.937.94
Operating Profit -0.69-8.60-1.61-1.02-2.43-5.58-3.41-2.41-2.89-3.90-5.37-5.32-2.51
OPM % -12,150.00%-96.04%-72.09%-45.99%-61.36%-81.76%-80.63%-61.79%-46.22%
Other Income 0.000.000.41-0.260.760.12-0.070.080.000.130.043.03-0.32
Interest 0.000.000.000.000.020.770.260.330.481.011.200.930.72
Depreciation 0.010.000.010.010.040.630.570.610.640.620.610.470.48
Profit before tax -0.70-8.60-1.21-1.29-1.73-6.86-4.31-3.27-4.01-5.40-7.14-3.69-4.03
Tax % 0.00%-28.37%7.44%-60.47%-33.53%-7.73%-27.38%-30.58%-24.94%-11.11%-26.05%-30.62%-34.24%
Net Profit -0.71-6.16-1.30-0.50-1.15-6.33-3.12-2.27-3.01-4.80-5.27-2.57-2.65
EPS in Rs -0.54-2.87-0.61-0.23-0.54-1.57-0.76-0.55-0.55-1.12-1.39-0.71-0.70

Last Updated: March 3, 2026, 3:43 pm

Quarterly Chart

Profit & Loss - Annual Report

Last Updated: February 25, 2026, 10:46 am

MetricMar 2022Mar 2023Mar 2024Mar 2025TTM
Sales 40151925
Expenses 410273243
Operating Profit 0-10-12-13-17
OPM % 3%-82%-66%-67%
Other Income 00003
Interest 00224
Depreciation 00222
Profit before tax 0-10-16-17-20
Tax % 0%-24%-24%-22%
Net Profit 0-8-12-14-15
EPS in Rs 0.15-3.52-2.26-3.06-3.92
Dividend Payout % 0%0%0%0%

Profit & Loss Yearly Chart

YoY Net Profit Growth

Year2023-20242024-2025
YoY Net Profit Growth (%)-50.00%-16.67%
Change in YoY Net Profit Growth (%)0.00%33.33%

Pharmaids Pharmaceuticals Ltd has shown a consistent positive trend in YoY Net Profit Growth (%) in the last 2 years from 2023-2024 to 2024-2025.

Growth

Compounded Sales Growth
10 Years:%
5 Years:%
3 Years:70%
TTM:102%
Compounded Profit Growth
10 Years:%
5 Years:%
3 Years:%
TTM:-33%
Stock Price CAGR
10 Years:35%
5 Years:70%
3 Years:67%
1 Year:53%
Return on Equity
10 Years:%
5 Years:%
3 Years:-20%
Last Year:-16%

Last Updated: September 5, 2025, 12:30 pm

Balance Sheet

Last Updated: December 4, 2025, 1:49 am

MonthMar 2022Mar 2023Mar 2024Mar 2025Sep 2025
Equity Capital 1021353535
Reserves -21372417
Borrowings 0093920
Other Liabilities 22112226
Total Liabilities 11259112098
Fixed Assets 00637755
CWIP 02753
Investments 03000
Other Assets 1119213941
Total Assets 11259112098

Reserves and Borrowings Chart

Cash Flow

MonthMar 2022Mar 2023Mar 2024Mar 2025
Cash from Operating Activity + -0-4-11-14
Cash from Investing Activity + 0-5-75-12
Cash from Financing Activity + 0217823
Net Cash Flow 012-8-3
Free Cash Flow -0-6-33-26
CFO/OP -200%41%86%109%

Free Cash Flow

MonthMar 2022Mar 2023Mar 2024Mar 2025
Free Cash Flow0.00-10.00-21.00-52.00

Free Cash Flow = Income Generated from Operational Activities - Borrowings - Capital Work in Progress (CWIP)

Consistent positive free cash flow is crucial for businesses as it indicates their ability to generate cash from their core operations. It provides financial flexibility, allowing companies to invest in growth opportunities, pay dividends to shareholders, reduce debt, and weather economic downturns more effectively.

Free Cash Flow Chart

Financial Efficiency Indicators

MonthMar 2022Mar 2023Mar 2024Mar 2025
Debtor Days 1246559
Inventory Days 910112359
Days Payable 236159480
Cash Conversion Cycle -2117-63
Working Capital Days -18-69-160
ROCE %-64%-26%-17%

Financial Efficiency Indicators Chart

Share Holding Pattern

MonthMar 2023Jun 2023Sep 2023Dec 2023Mar 2024Jun 2024Sep 2024Dec 2024Mar 2025Jun 2025Sep 2025Dec 2025
Promoters 9.95%9.94%9.70%9.25%5.64%5.56%5.19%5.22%5.22%5.14%32.99%32.99%
Public 90.05%90.07%90.31%90.75%94.36%94.44%94.81%94.79%94.78%94.87%67.00%67.01%
No. of Shareholders 7,7617,4767,3937,2817,5677,5948,0498,3498,2208,0268,0278,288

Shareholding Pattern Chart

No. of Shareholders

Pharmaids Pharmaceuticals Ltd: Intrinsic Value & Share Price Analysis - Shareholder trend analysis

This stock is not held by any mutual fund.

ROCE Trend

EPS Trend

Key Financial Ratios

MonthMar 25Mar 24Mar 23Mar 22
FaceValue 10.0010.0010.0010.00
Basic EPS (Rs.) -3.05-3.56-5.860.14
Diluted EPS (Rs.) -3.05-3.56-5.860.14
Cash EPS (Rs.) -3.14-2.87-3.520.15
Book Value[Excl.RevalReserv]/Share (Rs.) 16.8219.9910.478.44
Book Value[Incl.RevalReserv]/Share (Rs.) 16.8219.9910.478.44
Revenue From Operations / Share (Rs.) 5.514.280.003.84
PBDIT / Share (Rs.) -3.59-3.50-4.610.14
PBIT / Share (Rs.) -4.28-3.98-4.620.13
PBT / Share (Rs.) -4.90-4.43-4.620.13
Net Profit / Share (Rs.) -3.83-3.36-3.520.14
NP After MI And SOA / Share (Rs.) -3.06-2.26-3.520.14
PBDIT Margin (%) -65.06-81.570.003.86
PBIT Margin (%) -77.61-92.990.003.63
PBT Margin (%) -88.85-103.370.003.56
Net Profit Margin (%) -69.44-78.360.003.68
NP After MI And SOA Margin (%) -55.41-52.720.003.68
Return on Networth / Equity (%) -18.16-11.05-33.641.67
Return on Capital Employeed (%) -16.56-17.61-44.091.64
Return On Assets (%) -8.99-8.72-30.721.30
Long Term Debt / Equity (X) 0.500.040.000.00
Total Debt / Equity (X) 0.590.070.000.00
Asset Turnover Ratio (%) 0.180.260.000.00
Current Ratio (X) 0.771.178.231.09
Quick Ratio (X) 0.350.858.230.72
Inventory Turnover Ratio (X) 2.470.000.000.00
Interest Coverage Ratio (X) -6.06-7.86-2135.7155.63
Interest Coverage Ratio (Post Tax) (X) -5.42-6.55-1631.2454.05
Enterprise Value (Cr.) 271.01182.3934.0112.44
EV / Net Operating Revenue (X) 13.9412.070.003.16
EV / EBITDA (X) -21.42-14.79-3.4481.73
MarketCap / Net Operating Revenue (X) 12.4512.140.003.26
Price / BV (X) 4.082.552.081.48
Price / Net Operating Revenue (X) 12.4512.140.003.26
EarningsYield -0.04-0.04-0.160.01

Profitability Ratios (%)

Liquidity Ratios

Liquidity Ratios (%)

Interest Coverage Ratios (%)

Valuation Ratios

About the Company - Qualitative Analysis

Pharmaids Pharmaceuticals Ltd. is a Public Limited Listed company incorporated on 01/03/1989 and has its registered office in the State of Karnataka, India. Company's Corporate Identification Number(CIN) is L52520KA1989PLC173979 and registration number is 173979. Currently company belongs to the Industry of Pharmaceuticals. Company's Total Operating Revenue is Rs. 2.34 Cr. and Equity Capital is Rs. 35.27 Cr. for the Year ended 31/03/2025.
INDUSTRYADDRESSCONTACT
PharmaceuticalsUnit 201, Brigade Rubix, 2nd Floor, 20/14, HMT Factory Main Road, Bengaluru Karnataka 560013Contact not found
Management
NamePosition Held
Dr. Shankarappa Nagaraja Vinaya BabuChairman, Non Ind & Non Exe Director
Ms. Mini ManikantanExecutive Director
Mr. Venu Madhava KaparthyExecutive Director
Mr. Shreedhara ShettyNon Exe.Non Ind.Director
Mr. Methuku NageshIndependent Director
Mr. P N VijayIndependent Director
Mr. Mopperthy SudheerIndependent Director

FAQ

What is the intrinsic value of Pharmaids Pharmaceuticals Ltd and is it undervalued?

As of 04 April 2026, Pharmaids Pharmaceuticals Ltd's intrinsic value is ₹14.20, which is 50.35% lower than the current market price of ₹28.60, suggesting the stock is overvalued. This is calculated using the PE ratio method factoring in ROE (16.3 %), book value (₹14.7), dividend yield (0.00 %), and 5-year EPS CAGR.

What is the current share price and 52-week range of Pharmaids Pharmaceuticals Ltd?

Pharmaids Pharmaceuticals Ltd is trading at ₹28.60 as of 04 April 2026, with a FY2026-2027 high of ₹73.4 and low of ₹27.1. The stock is currently near its 52-week low. Market cap stands at ₹101 Cr..

How does Pharmaids Pharmaceuticals Ltd's P/E ratio compare to its industry?

Pharmaids Pharmaceuticals Ltd has a P/E ratio of , which is below the industry average of 53.84. This is broadly in line with or below the industry average.

Is Pharmaids Pharmaceuticals Ltd financially healthy?

Key indicators for Pharmaids Pharmaceuticals Ltd: ROCE of 17.4 % indicates efficient capital utilization; ROE of 16.3 % shows strong shareholder returns. Dividend yield is 0.00 %.

Is Pharmaids Pharmaceuticals Ltd profitable and how is the profit trend?

Pharmaids Pharmaceuticals Ltd reported a net profit of ₹-14 Cr in Mar 2025 on revenue of ₹19 Cr. Compared to ₹0 Cr in Mar 2022, the net profit shows a mixed trend.

Does Pharmaids Pharmaceuticals Ltd pay dividends?

Pharmaids Pharmaceuticals Ltd has a dividend yield of 0.00 % at the current price of ₹28.60. The company is currently not paying meaningful dividends.

Disclaimer: This article is for informational purposes only and should not be construed as financial advice. The author is not a SEBI registered financial advisor and does not have any vested interest in Pharmaids Pharmaceuticals Ltd. Investors are advised to conduct their own due diligence and consult with a financial professional before making any investment decisions. The information provided in this article is based on publicly available data and the author's analysis, but it may not be comprehensive or up-to-date. The author and getaka.co.in are not responsible for any errors or omissions in the content. This article is not intended to promote any particular investment strategy or recommendation, and readers should consult with their own financial advisors before making any investment decisions. Data Source: NSE
Explore Industry-wise Stock Analysis Reports